Journal of Clinical Pathways. 2017;3(6):12-16.
Reviewing the Latest Research on Value-Based Care, Clinical Pathways, and Precision Medicine
A blood-based proteomic test offers prognostic information and optimal second-line treatment guidance for patients with squamous cell carcinoma of the lung.
A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years at a significantly high cost.
A recent report demonstrates the promise of programmed death inhibition in improving outcomes for patients with gray zone lymphoma, a rare, difficult-to-treat type of lymphoma.
Survivors of chronic cancer are often not receiving optimal survivorship care plans and follow-up treatment.
A recent clinical trial of a chimeric antigen receptor T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma independent of disease type, stage, or characteristics.
Risk-reducing mastectomy performed within 5 years of ovarian cancer diagnosis does not appear to be cost-effective when compared with surveillance for patients harboring BRCA mutations.
Researchers identified which imaging technique is better for evaluating prognosis of newly-diagnosed multiple myeloma.
Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination.
Patients with advanced melanoma who are treated with the immunotherapeutic agent nivolumab after their first disease progression may experience tumor response without compromising safety.
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis.